The association between statin use and non-Hodgkin lymphoma; a systematic review and meta-analysis

Abstract

Introduction: Statins reduce the cancer risk; however, non-Hodgkin lymphoma (NHL) evidence remains controversial. Therefore, we aimed to evaluate the relationship between statin consumption and NHL risk using a systematic review and meta-analysis. Materials and Methods: In this systematic review and meta-analysis, international databases, including Scopus, PubMed, Web of Science, Cochrane, and Google Scholar search engines, were searched without a time limit up to September 21, 2023. Data analysis was performed using STATA 14 software, and the significance level was considered P<0.05. Results: The results of combining 13 studies (9 case-control studies and 4 cohort studies) with a total sample size of 1 142 740 subjects showed that statin consumption could reduce NHL risk by 22 (RR: 0.78; 95 CI: 0.69, 0.88). Statin consumption in cohort studies reduced NHL risk by 14 (RR: 0.86; 95 CI: 0.77, 0.95), but in case-control studies, it reduced NHL risk by 26 (RR: 0.74; 95 CI: 0.62, 0.90). Furthermore, statin consumption reduced diffuse large B-cell lymphoma risk by 24 (RR: 0.76; 95 CI: 0.67, 0.87) and marginal zone risk by 26 (RR: 0.74; 95 CI: 0.59, 0.93). However, it did not affect reducing the risk of chronic lymphocytic leukemia/small lymphocytic lymphoma (RR: 0.94; 95 CI: 0.85, 1.05), follicular (RR: 0.96; 95 CI: 0.83, 1.10), plasma cell neoplasms (RR: 0.97; 95 CI: 0.70, 1.33), T cell lymphoma (RR: 0.81; 95 CI: 0.55, 1.19) and B cell lymphoma (RR: 0.94; 95 CI: 0.44, 2.01). Conclusion: Statin consumption significantly reduced the risk of NHL, diffuse large B-cell lymphoma, and marginal zone but did not affect other NHL types. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023469126) and Research Registry (UIN: reviewregistry1732) website. © 2024 The Author(s).